Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

BACKGROUND: About 40% of all patients with chronic myeloid leukemia are currently old or very old. They are effectively treated with imatinib, even though underrepresented in clinical studies. Furthermore, as it happens in the general population, they often receive multiple drugs for associated chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Iurlo, Alessandra, Nobili, Alessandro, Latagliata, Roberto, Bucelli, Cristina, Castagnetti, Fausto, Breccia, Massimo, Abruzzese, Elisabetta, Cattaneo, Daniele, Fava, Carmen, Ferrero, Dario, Gozzini, Antonella, Bonifacio, Massimiliano, Tiribelli, Mario, Pregno, Patrizia, Stagno, Fabio, Vigneri, Paolo, Annunziata, Mario, Cavazzini, Francesco, Binotto, Gianni, Mansueto, Giovanna, Russo, Sabina, Falzetti, Franca, Montefusco, Enrico, Gugliotta, Gabriele, Storti, Sergio, D'Addosio, Ada M., Scaffidi, Luigi, Cortesi, Laura, Cedrone, Michele, Rossi, Antonella Russo, Avanzini, Paolo, Mauro, Endri, Spadea, Antonio, Celesti, Francesca, Giglio, Gianfranco, Isidori, Alessandro, Crugnola, Monica, Calistri, Elisabetta, Sorà, Federica, Rege-Cambrin, Giovanna, Sica, Simona, Luciano, Luigiana, Galimberti, Sara, Orlandi, Ester M., Bocchia, Monica, Tettamanti, Mauro, Alimena, Giuliana, Saglio, Giuseppe, Rosti, Gianantonio, Mannucci, Pier Mannuccio, Cortelezzi, Agostino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346773/
https://www.ncbi.nlm.nih.gov/pubmed/27579540
http://dx.doi.org/10.18632/oncotarget.11657

Ejemplares similares

Ejemplares similares